The original drug price reduction, multinational pharmaceutical sales strategy attracted attention

Recently, Shaanxi Provincial Health Insurance Bureau published the province's September drug monitoring report on its website.
through the province's 40 drug price monitoring points, Shaanxi drugstores 193 monitoring products regulations, medical institutions 200 monitoring products regulations for monitoring.
According to monitoring data, although the average price of Western medicine in medical institutions in the province showed a trend of increasing or decreasing more than the same period last year, but individual drugs showed a larger increase, such as sodium bicarbonate injections (12.5g:250ml/bottle, pharmaceutical) increased by 17.55 yuan, or 295.03 percent, over the same period last year.
, it is worth noting that from the data can be found that in the past multinational pharmaceutical companies have been adhered to the original research varieties prices in the off-hospital market has begun to loosen.
According to the monitoring report, the province's Copper River City pharmacy sales of Entekawe tablets (0.5mg x 7 tablets / box, China and the United States Shanghai Shiguibao Pharmaceuticals) and other 4 product standard price reduction, an average decline of 3.20%;
this, industry experts believe that in the face of the national collection released the effect of price reduction, from the hospital market gradually switched to retail pharmacies multinational pharmaceutical companies are also feeling the pressure to reduce prices, and make adjustments.
Although previously in the third batch of volume procurement quotations, a number of foreign pharmaceutical companies quotations fell very small, a large number of products have taken high-priced, current price quotation measures, a small number of symbolic choice to reduce the price of about 10%, almost equivalent to a direct abandonment of the market decision, but in the collection of the initiative to reduce the price of the original research enterprises also began to emerge.
Such as Pfizer's Lyne amine oral regular release agent type on the price of 31.25 yuan / tablet, compared to the limit price of 319.517 yuan / tablet, a decline of more than 90%, has become the first of many pharmaceutical companies in the higher decline of enterprises.
addition, since April 2020, Sanofi has also slashed the prices of Aberno and Bolvi, two classics in the field of chronic diseases, in Beijing, Shanghai, Chengdu and Chongqing, by about 60% and 70%, respectively.
lilly injections with pyrethroids, Novarma's methicillin tablets have also been cutting prices in a number of places.
this, analysts believe that with the consistent evaluation policy, as well as the further expansion of the pilot procurement, the future drug price reduction, especially the high price of imported raw research drugs will be further increased.
In fact, the original drug has been good efficacy, high prices to many patients, but as the country through a variety of ways to reduce drug prices and generic drug consistency evaluation, the original drug compared with generic drugs, its advantages are increasingly weakened.
, more and more original pharmaceutical companies to join the volume of procurement.
with the implementation of the national drug belt procurement policy, the patent period of the original drug research in China for a long time to maintain a high premium era is coming to an end.
Multinational pharmaceutical companies to deal with the attitude of volume procurement, from wait-and-see gradually to proactive change, to join the volume of procurement of the original research drugs are also more and more, such as Bai Tangping, Boliwei, etc. are through the volume of procurement to achieve a substantial reduction in prices.
, on the other hand, generics accounted for the majority of the winning bids for multi-wheeled strip purchases, which meant that many of the original drugs lost their in-house markets.
, for these enterprises, the out-of-hospital market has become a top priority, and the export of a large number of out-of-hospital channels, including price reduction preferential policies, will become an important means.
in general, under the influence of a variety of factors, multinational pharmaceutical companies rely on patent expired original research drugs "lying down to make money" days are gone.
industry believes that multinational drug companies that rely on patented expired drugs to generate profits will have to change their strategies and focus their businesses on innovative drugs that are highly effective and reasonably priced.
, with the introduction of a series of government policies conducive to the listing of innovative drugs, how multinational pharmaceutical companies respond to the changing market will become the focus of attention in the industry.